Quanterix has announced the acquisition of Akoya Biosciences, Inc. According to the company announcement Quanterix Corporation is a Billerica, Massachusetts-based company focused on advancing scientific discovery through ultra-sensitive biomarker detection. The company’s core technology, Simoa, provides unparalleled sensitivity and flexibility for earlier biomarker detection in blood, serum, or plasma, enabling the quantification of proteins at extremely low levels. Quanterix offers industry-leading precision instruments, digital immunoassay technology, and a CLIA-certified Accelerator laboratory, supporting research in various therapeutic areas including neurology, oncology, immunology, cardiology, and infectious disease. With the recent acquisition of Akoya Biosciences, Quanterix aims to deliver comprehensive protein biomarker solutions by leveraging signatures in both blood and tissue, thereby expanding its served addressable market from $1 billion to $5 billion. Quanterix has been a trusted partner in the scientific community for nearly two decades, with its technology powering research published in over 3,400 peer-reviewed journals.

To learn more about Quanterix, visit http://www.quanterix.com/
Company LinkedIn Page: https://www.linkedin.com/company/quanterix/

Company Contact:

Masoud Toloue, Chief Executive Officer
617-301-9400

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.